AtaiBeckley Inc. (ATAI)
NASDAQ: ATAI · Real-Time Price · USD
3.570
+0.010 (0.28%)
Mar 19, 2026, 4:00 PM EDT - Market closed
AtaiBeckley Revenue
In the year 2025, AtaiBeckley had annual revenue of $4.09M with 1,227.60% growth. AtaiBeckley had revenue of $1.07M in the quarter ending December 31, 2025.
Revenue (ttm)
$4.09M
Revenue Growth
+1,227.60%
P/S Ratio
317.09
Revenue / Employee
$41,303
Employees
99
Market Cap
1.30B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.09M | 3.78M | 1,227.60% |
| Dec 31, 2024 | 308.00K | -6.00K | -1.91% |
| Dec 31, 2023 | 314.00K | 81.00K | 34.76% |
| Dec 31, 2022 | 233.00K | -20.14M | -98.86% |
| Dec 31, 2021 | 20.38M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ardelyx | 407.32M |
| Monte Rosa Therapeutics | 123.67M |
| Vir Biotechnology | 68.56M |
| Immatics | 56.67M |
| Zenas BioPharma | 10.00M |
| Taysha Gene Therapies | 9.77M |
ATAI News
- 20 hours ago - AtaiBeckley: BPL-003 Phase 3 Momentum Keeps Me Bullish - Seeking Alpha
- 9 days ago - BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day - GlobeNewsWire
- 13 days ago - AtaiBeckley Inc. (ATAI) Analyst/Investor Day Transcript - Seeking Alpha
- 13 days ago - AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update - GlobeNewsWire
- 20 days ago - AtaiBeckley Inc. (ATAI) Discusses Positive Topline Results From Exploratory Phase IIa Study of EMP-01 in Social Anxiety Disorder Transcript - Seeking Alpha
- 21 days ago - AtaiBeckley Touts Social Anxiety Breakthrough With Phase 2 Trial Data - Benzinga
- 21 days ago - AtaiBeckley Announces Positive Topline Results from an Exploratory Phase 2a Trial of EMP-01 (oral R-MDMA) in Social Anxiety Disorder - GlobeNewsWire
- 27 days ago - AtaiBeckley To Host Virtual Investor Day on March 6, 2026 - GlobeNewsWire